Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Scott D SolomonJohn Joseph Valentine McMurrayBrian ClaggettRudolf A de BoerDavid DeMetsAdrian F HernandezSilvio E InzucchiMikhail N KosiborodCarolyn S P LamFelipe MartinezSanjiv J ShahAkshay S DesaiPardeep S JhundJan BelohlavekChern-En ChiangC Jan Willem BorleffsJosep Comin-ColetDan DobreanuJaroslaw DrozdzJames C FangMarco Antonio Alcocer-GambaWaleed Al HabeebYaling HanJose Walter Cabrera HonorioStefan P JanssensTzvetana KatovaMasafumi KitakazeBéla MerkelyEileen O'MearaJose Francisco Kerr SaraivaSergey N TereshchenkoJorge ThiererMuthiah VaduganathanOrly VardenySubodh VermaVinh Nguyen PhamUlrica WilderängNatalia ZaozerskaErasmus BachusDaniel LindholmMagnus PeterssonAnna Maria Langkildenull nullPublished in: The New England journal of medicine (2022)
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).